Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology 47 , 1595–1603 (2008). Article Google Scholar ...

Nonselective beta blockers or endoscopic band ligation (EVL) are recommended for primary prophylaxis of variceal bleeding in patients with esophageal varices. However, it has been found that ...

In the cirrhotic patient hemorrhage is usually thought to be secondary to esophageal varices although peptic ulcer and cancer are always considered in the differential diagnosis. The erroneous ...

Aim: To investigate if esophageal varices can be evaluated using external contrast-enhanced ultrasonography with Levovist and coded harmonic angio (CHA). Methods: Subjects were six healthy adult ...

The clinical and autopsy records of patients in whom the diagnosis of esophageal varices was made from 1950 to 1957 at this hospital were examined. The records of the 50 patients in whom the tube ...

Patients with cirrhosis often develop abnormal veins known as varices in the esophagus that can bleed and require immediate intervention. The current treatment calls for the banding of varices ...

Gastric varices are present at the time of screening endoscopy in approximately 25% of patients with known cirrhosis; 18% of patients with known cirrhosis have both esophageal and gastric varices.

Researchers at the Medical University of South Carolina have revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a ...

Esophageal varices are extremely dilated sub-mucosal veins in the lower third of the esophagus. They are most often a consequence of portal hypertension, commonly due to cirrhosis. People with ...

Liver fibrosis causes scar tissue to form on the liver, sometimes leading to chronic liver disease. Learn about noninvasive ...

Black poop doesn't always mean there is an underlying medical concern. There are some foods, supplements, and medications ...

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial ...